SightGlass Vision studies find DOT spectacle lenses as highly effective for myopia management, show no evidence of rebound

DOT lenses achieved 75% efficacy in children after 12 months in a Chinese study. Image credit: SightGlassVision

SightGlass Vision’s new clinical study demonstrates that the company’s Diffusion Optics Technology (DOT™ 0.2) spectacle lenses are highly effective for myopia management in preliminary findings, achieving 75% efficacy in children after 12 months in China.¹ A separate study also demonstrates no evidence of rebound (ie, myopia progression did not accelerate after ceasing wear) in children in North America. Both studies will be presented at ARVO 2025, according to a news release.

“Eye care professionals in a growing number of markets trust DOT lenses, and this latest data further builds the well-established science behind our technology,” said Andrew Sedgwick, chief executive officer of SightGlass Vision, in the release. “Clinical investigators have seen an extremely positive response to our approach among Chinese children—a remarkable 75% reduction in myopia progression after 1-year of wear­. Additionally, researchers observed treatment benefit was retained after North American children stopped DOT lens wear. This is a durable, evidence-based myopia management intervention that can improve children’s lives worldwide.”

SightGlass Vision’s CATHAY trial builds on data collected from its 4-year North American CYPRESS study by examining DOT lens efficacy in China. The study evaluated 186 myopic children, 6 to 13 years old at initiation, across 5 hospitals. Results showed a significant slowing of myopia progression when using DOT lenses compared to single vision spectacle lenses with a 75% reduction in cycloplegic spherical equivalent refraction (cSER) and a decrease of −0.48D (p<0.0001). Additionally, the study demonstrated a 74% reduction in axial length (AL), with a decrease of 0.26 mm (p<0.0001).¹

The CATHAY study is expected to continue for 24 months and supports the outcomes from the first year of the CYPRESS study.¹

Another study, “Myopia Progression 1-Year After Cessation of Contrast Modulation Spectacle Lenses,” followed a subset of children who participated in the CYPRESS multicenter trial for an additional 12 months. The control group continued wearing single-vision spectacle lenses with the DOT group crossed over to wearing the same lenses. After 1 year of discontinued DOT spectacle lens wear, cSER and AL progression in the test group reverted to age-normative rates observed in the control group, indicating no statistically or clinically significant rebound effect.¹

SightGlass Vision is also investing in research on short-term subfoveal choroidal thickness (SFCT) variation, which may act as an early biomarker for successfully controlling eye growth and myopia progression. “Subfoveal Choroidal Thickening After Short-Term Wear of Contrast and Defocus-Modulating Myopia Control Spectacle Lenses” evaluated 31 children who wore DOT and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for 12 hours per day. Both groups exhibited a significant increase in SFCT after 1 week compared to single vision lens use.¹

“Week after week, we are seeing mounting enthusiasm for DOT spectacle lenses from eye care professionals. These relevant and rigorous scientific outcomes, combined with their own experiences, helps them more quickly adopt and confidently recommend the technology,” said Sedgwick in the release.

The lenses use thousands of light-scattering elements to reduce contract signaling on the retina, which is an evidence-backed mechanism of action to slow myopia progression in children.¹

Previous findings have demonstrated that the DOT lenses significantly reduce myopia progression over 36 months in children as young as 6 years old, with 65% of children having no clinically meaningful myopia progression after 1 year. Additionally, myopia progression was found to reduce by 59% over 2 years when worn full time, with 93% of children saying that they love their glasses.²

References:

1. New studies demonstrate 75% myopia management efficacy with Chinese children after 12 months and no evidence of rebound effect in North American children for SightGlass Vision DOT lenses. News release. SightGlass Vision. May 1, 2025. Accessed May 1, 2025.

2. Diffusion Optics Technology. SightGlass Vision. Accessed May 1, 2025. https://www.sightglassvision.com/diffusion-optics-technology/